Open Access

Celecoxib suppresses lipopolysaccharide‑stimulated oral squamous cell carcinoma proliferation in vitro and in vivo

  • Authors:
    • Hisato Yoshida
    • Hitoshi Yoshimura
    • Shinpei Matsuda
    • Satoshi Yamamoto
    • Masahiro Ohmori
    • Keiichi Ohta
    • Takashi Ryoke
    • Hayato Itoi
    • Tamotsu Kiyoshima
    • Motohiro Kobayashi
    • Kazuo Sano
  • View Affiliations

  • Published online on: October 10, 2019     https://doi.org/10.3892/ol.2019.10975
  • Pages: 5793-5800
  • Copyright: © Yoshida et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Periodontitis is one of the most common chronic oral inflammatory conditions worldwide and is associated with a risk of developing oral squamous cell carcinoma (OSCC). Porphyromonas gingivalis is a major pathogen in periodontitis, and its lipopolysaccharide (LPS) promotes the expression of cyclooxygenase‑2 (COX‑2) in OSCC both in vivo and in vitro. Celecoxib is a selective COX‑2 inhibitor; however, its antitumor effects on P. gingivalis LPS‑stimulated OSCC and the underlying molecular mechanism remain unclear. To elucidate the association between periodontitis and OSCC, the effect of P. gingivalis‑derived LPS on OSCC cell proliferation was examined both in vitro and in vivo in the present study. The expression levels of COX‑2 and p53 in OSCC cells with/without celecoxib treatment were determined via western blotting. The therapeutic potential of celecoxib in LPS‑stimulated OSCC was evaluated by staining for Ki‑67 and p21, as well as with terminal deoxynucleotidyl‑transferase‑mediated dUTP nick end labeling staining. LPS treatment significantly increased OSCC cell proliferation in vitro, and celecoxib significantly inhibited cell proliferation with/without LPS treatment. Celecoxib treatment of OSCC cells downregulated the protein expression levels of COX‑2 compared with untreated cells, but there was little change in p53 expression. In the mouse xenograft model, oral administration of celecoxib significantly suppressed tumor growth, reduced the expression of Ki‑67, increased the apoptosis index and induced p21 expression with/without LPS treatment. The results from the present study demonstrate that P. gingivalis' LPS can stimulate tumor growth by interacting with OSCC cells. In conclusion, these results suggest that celecoxib could be used for the effective prevention and treatment of LPS‑stimulated OSCC.

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yoshida, H., Yoshimura, H., Matsuda, S., Yamamoto, S., Ohmori, M., Ohta, K. ... Sano, K. (2019). Celecoxib suppresses lipopolysaccharide‑stimulated oral squamous cell carcinoma proliferation in vitro and in vivo. Oncology Letters, 18, 5793-5800. https://doi.org/10.3892/ol.2019.10975
MLA
Yoshida, H., Yoshimura, H., Matsuda, S., Yamamoto, S., Ohmori, M., Ohta, K., Ryoke, T., Itoi, H., Kiyoshima, T., Kobayashi, M., Sano, K."Celecoxib suppresses lipopolysaccharide‑stimulated oral squamous cell carcinoma proliferation in vitro and in vivo". Oncology Letters 18.6 (2019): 5793-5800.
Chicago
Yoshida, H., Yoshimura, H., Matsuda, S., Yamamoto, S., Ohmori, M., Ohta, K., Ryoke, T., Itoi, H., Kiyoshima, T., Kobayashi, M., Sano, K."Celecoxib suppresses lipopolysaccharide‑stimulated oral squamous cell carcinoma proliferation in vitro and in vivo". Oncology Letters 18, no. 6 (2019): 5793-5800. https://doi.org/10.3892/ol.2019.10975